The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Here are the top 5 biosimilar articles for the week of June 23, 2025.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

The Top 5 Biosimilar Articles for the Week of September 9

September 13th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of September 9, 2024.

Comparable Disease Activity, Drug Persistence in Patients With JIA Who Switch to Biosimilars

September 12th 2024

By Skylar Jeremias

Article

Switching children with juvenile idiopathic arthritis (JIA) from anti–tumor necrosis factor originators to biosimilars showed similar disease activity and drug persistence, with good tolerability, supporting the safety and effectiveness of non-medical switching.

The Future of Biosimilar Gene Therapies: Key Issues and Potential

September 11th 2024

By Skylar Jeremias

Article

While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.

Patients With nAMD Successfully Switch From Aflibercept to Ranibizumab

September 10th 2024

By Cameron Santoro

Article

A study found patients with neovascular age-related macular degeneration (nAMD) successfully switched from aflibercept to the biosimilar ranibizumab, despite fluid challenges.

BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars

September 9th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.

Promoting Informed Decision-Making Through Biosimilar Awareness

September 8th 2024

By Cameron Santoro

Video

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, urges stakeholders to provide patient advocacy groups with comprehensive information about specific drugs and drug classes to increase patient understanding of biosimilars and promote informed decision-making.

Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD

September 7th 2024

By Deana Ferreri, PhD

Article

Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).

The Top 5 Biosimilar Articles for the Week of September 2

September 6th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of September 2, 2024.

Switching From Originator Etanercept to Biosimilar Version Proves Safe, Effective in RA

September 5th 2024

By Skylar Jeremias

Article

Patients with rheumatoid arthritis who switched from the etanercept originator to a biosimilar exhibited similar disease activity and drug persistence compared with those who remained on the originator, indicating that nonmedical switching does not negatively impact treatment outcomes.

The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings

September 4th 2024

By Skylar Jeremias

Article

A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.